WOCKPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | WOCKPHARMA | Market Cap | 19,805 Cr. | Current Price | 1,219 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 98.5 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,339 ₹ | DMA 200 | 1,380 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 54.0 Cr. |
| RSI | 35.0 | MACD | -44.0 | Volume | 4,41,631 | Avg Vol 1Wk | 5,94,732 |
| Low price | 1,154 ₹ | High price | 1,870 ₹ | PEG Ratio | 4.08 | Debt to equity | 0.76 |
| 52w Index | 8.96 % | Qtr Profit Var | 273 % | EPS | 11.8 ₹ | Industry PE | 27.6 |
📊 Analysis: WOCKPHARMA shows weak intraday potential. Current price (₹1,219) is below both DMA50 (₹1,339) and DMA200 (₹1,380), reflecting short-term and medium-term weakness. RSI at 35.0 indicates oversold territory, while MACD (-44.0) confirms strong bearish momentum. Volume today (4.41L) is below the 1-week average (5.94L), suggesting reduced participation. Fundamentals are weak with ROCE (4.40%) and negative ROE (-0.53%), while valuation is stretched at P/E 98.5 vs industry 27.6. Debt-to-equity (0.76) adds further risk.
💡 Optimal Buy Price: ₹1,210–₹1,215 if price stabilizes near support.
🎯 Profit Exit Levels: ₹1,235 (first target), ₹1,250 (second target).
🛡️ Stop-Loss: ₹1,200 to protect against downside risk.
⏱️ If Already Holding: Consider exiting near ₹1,235 if momentum weakens. If price fails to hold above ₹1,215 with declining volume, exit early to avoid intraday losses.
✅ Positive
- EPS (₹11.8) supports earnings visibility despite weak fundamentals.
- Quarterly profit variation (+273%) shows improvement compared to prior losses.
- 52-week index gain of 8.96% reflects sectoral resilience.
⚠️ Limitation
- High P/E (98.5) compared to industry average (27.6) indicates severe overvaluation.
- PEG ratio (4.08) signals expensive growth prospects.
- Price trading below DMA50 & DMA200 shows technical weakness.
- Low ROCE (4.40%) and negative ROE (-0.53%) highlight poor capital efficiency.
- Debt-to-equity (0.76) adds leverage risk.
📉 Company Negative News
- Quarterly PAT declined (₹54 Cr. → ₹38 Cr.), showing earnings pressure.
- FII holding reduced (-0.10%) and DII holding reduced (-0.45%), reflecting cautious institutional sentiment.
📈 Company Positive News
- Quarterly profit variation (+273%) highlights recovery momentum.
- EPS (₹11.8) remains stable relative to book value.
🏭 Industry
- Industry P/E at 27.6 is much lower than company’s, suggesting peers may be more attractively valued.
- Sector shows steady growth outlook, supported by healthcare demand.
🔎 Conclusion
WOCKPHARMA is fundamentally weak and technically bearish for intraday trades. The stock is oversold and may offer short-term bounce opportunities, but stretched valuation and poor efficiency limit sustainability. Suitable only for cautious entries near support with strict stop-loss discipline. Momentum traders should wait for RSI recovery and MACD reversal before committing to larger intraday positions.
Would you like me to extend this into a peer benchmarking overlay for WOCKPHARMA against other pharma sector stocks, so you can compare relative intraday strength and compounding potential?